EUVIMEDEUVIMED entdecken
Crossref

Targeting p53/p21 Signaling: Linarin as a Novel Modulator of 5-FU Sensitization in Colorectal Cancer

Amir Valizadeh, Mohammad Rahmati-Yamchi, Alireza Ali Hemmati, Mohammad Ebrahimnejad, Ali Yousefzadeh, Mehran Molavand, Bahman Yousefi

Advanced Pharmaceutical Bulletin · 09.08.2026

DOI: 10.34172/apb.47354 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 09.08.2026. Verfasst von Amir Valizadeh und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We assessed linarin, a plant-derived flavone glycoside, for its ability to overcome intrinsic 5-fluorouracil (5-FU) resistance by reinstating p53/p21-mediated tumor suppression in colorectal cancer (CRC) cell models, and we explicitly present these findings as a mechanistic proof of concept within a defined in vitro scope.

Methods

Cell viability was measured using the MTT assay; synergy was assessed using the combination index (CI) with isobologram validation; and programmed cell death was evaluated by internucleosomal DNA fragmentation ELISA and Western blot analysis of caspase-dependent markers. Underlying pathways were probed by immunoblotting, quantitative RT-PCR, and targeted siRNA-mediated knockdown of p53 and p21, complemented by pharmacological inhibition with pifithrin-α and UC2288.

Results

Linarin induced concentration-dependent cell killing in CRC lines, yielding IC₅₀ values of 122.8–210.2 μM at 48 hours, alongside selective sparing of normal colon cells (NCM460; selectivity index approximately 2.0–3.3-fold). The p53 status-dependent sensitivity gradient (HCT116 wild-type < SW480 mutant < HCT116 p53⁻/⁻) provided initial evidence of p53-dependent cytotoxicity. Dual therapy with 5-FU yielded robust synergy (CI 0.52–0.88) in p53-proficient lines, with near-additive effects in p53-null cells (CI 0.77), and notably reduced the 5-FU IC₅₀ in intrinsically resistant LoVo cells from 19.0 μM to 5.7 μM. Linarin promoted p53 stabilization and Ser15/Ser20 phosphorylation, elevated p21 mRNA levels to 5.4-fold the control level, and suppressed MDM2 mRNA levels to 0.42-fold the control level. This was accompanied by caspase-dependent cell death and amplified DNA damage signaling (elevated γ-H2AX). Functional validation via siRNA knockdown and pharmacological inhibition confirmed the centrality of the p53/p21 pathway in linarin's sensitizing action in p53-competent cells.

Conclusion

As a mechanistic proof-of-concept, linarin demonstrates the capacity to potentiate 5-FU cytotoxicity by reactivating the p53/p21 pathway in CRC models harboring functional p53. Future investigations should prioritize models of acquired resistance and formulation optimization to advance these findings toward preclinical translation.

Zitieren

APA

Valizadeh, A., Rahmati-Yamchi, M., Hemmati, A. A., Ebrahimnejad, M., Yousefzadeh, A., Molavand, M., & Yousefi, B. (2026). Targeting p53/p21 Signaling: Linarin as a Novel Modulator of 5-FU Sensitization in Colorectal Cancer. Advanced Pharmaceutical Bulletin. https://doi.org/10.34172/apb.47354

Vancouver

Valizadeh A, Rahmati-Yamchi M, Hemmati AA, Ebrahimnejad M, Yousefzadeh A, Molavand M, et al. Targeting p53/p21 Signaling: Linarin as a Novel Modulator of 5-FU Sensitization in Colorectal Cancer. Advanced Pharmaceutical Bulletin. 2026. doi:10.34172/apb.47354

BibTeX
@article{Valizadeh2026,
  author = {Valizadeh, Amir and Rahmati-Yamchi, Mohammad and Hemmati, Alireza Ali and Ebrahimnejad, Mohammad and Yousefzadeh, Ali and Molavand, Mehran and Yousefi, Bahman},
  title = {Targeting p53/p21 Signaling: Linarin as a Novel Modulator of 5-FU Sensitization in Colorectal Cancer},
  journal = {Advanced Pharmaceutical Bulletin},
  year = {2026},
  doi = {10.34172/apb.47354}
}
Kostenlos starten →